Guggenheim Capital’s Repros Therapeutics Inc. RPRX Stock Holding History

Guggenheim Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-20,254	Closed	-$20K	–	3040
2016 Q1	$20K	Sell	20,254 -64,583	-76%	-$63K	﹤0.01%	2828
2015 Q4	$103K	Sell	84,837 -13,189	-13%	-$42.3K	﹤0.01%	2833
2015 Q3	$728K	Sell	98,026 -7,427	-7%	-$56.8K	﹤0.01%	2267
2015 Q2	$755K	Buy	105,453 +2,126	+2%	+$16.6K	﹤0.01%	2369
2015 Q1	$887K	Buy	103,327 +22,974	+29%	+$205K	﹤0.01%	2299
2014 Q4	$802K	Buy	+80,353	New	+$685K	﹤0.01%	2330
2014 Q3	–	Sell	-11,953	Closed	-$206K	–	3321
2014 Q2	$206K	Sell	11,953 -1,141	-9%	-$18.6K	﹤0.01%	2898
2014 Q1	$233K	Buy	13,094 +2,170	+20%	+$42K	﹤0.01%	2838
2013 Q4	$200K	Buy	10,924 +1,290	+13%	+$24.4K	﹤0.01%	2851
2013 Q3	$258K	Buy	+9,634	New	+$206K	﹤0.01%	2652

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Guggenheim Capital's RPRX Position: Q2 2016 in Review

Guggenheim Capital sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 20,254 shares — an estimated $20K sold.

Guggenheim Capital first reported a position in RPRX in Q3 2013 and held it in 10 quarters. The position peaked at $887K in Q1 2015. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

Guggenheim Capital reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
Guggenheim Capital sold 20,254 Repros Therapeutics Inc. shares in Q2 2016, an estimated $20K.
Guggenheim Capital first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 10 quarters.
Guggenheim Capital's Repros Therapeutics Inc. position peaked at $887K in Q1 2015.
43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on Guggenheim Capital's 13F filing for Q2 2016, filed 15 Aug 2016.